Background: Transurethral resection of the prostate (TURP) is considered to be the standard treatment for patients with benign prostatic obstruction (BPO) ≤80 mL. However, up to 14.7% of the patients require secondary TURP due to recurrent BPO. The aim of our study was to describe specific features of holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP) in patients with recurrent BPO after previous prostate surgery. Materials and Methods: A total of 768 consecutive patients from our prospective collected database were retrospectively reviewed and divided into 4 groups: group A (489 patients) and group C (253 patients) underwent primary HoLEP and ThuLEP treatment, while group B (17 patients) and D (9 patients) included patients with recurrent BPO who were treated with HoLEP and ThuLEP, respectively. Results: There were no significant differences in preoperative parameters between the groups at primary (A and C) and secondary (B and D) treatment except their age. At 6-month follow-up, voiding parameters and symptom scores showed statistically significant improvements compared to baseline without differences between the groups. The mean operative time was comparable between the groups and did not differ significantly (p > 0.05). Conclusions: Laser enucleation for the treatment of recurrent BPO is feasible and seems to be a safe and effective procedure.

Keywords:
Benign prostatic obstruction, Recurrent adenoma, Endoscopic laser enucleation
1.
Gravas S, Bach T, Bachmann A, Drake MJ, Gacci M, Gratzke C, et al: Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) EAU 2016. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/.
2.
Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al: Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008; 180: 246–249.
3.
Coskuner ER, Ozkan TA, Koprulu S, Dillioglugil O, Cevik I: The role of the bipolar plasmakinetic TURP over 100 g prostate in the elderly patients. Int Urol Nephrol 2014; 46: 2071–2077.
4.
Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR: Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 2012; 109: 408–411.
5.
Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M, et al: Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005; 47: 499–504.
6.
Gross AJ, Orywal AK, Becker B, Netsch C: Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction. World J Urol 2017; 35: 1585–1593.
7.
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al: A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–1096.
8.
Jaeger CD, Krambeck AE: Holmium laser enucleation of the prostate for persistent lower urinary tract symptoms after prior benign prostatic hyperplasia surgery. Urology 2013; 81: 1025–1029.
9.
Elshal AM, Elmansy HM, Elhilali MM: Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH). BJU Int 2012; 110:E845–E850.
10.
Elkoushy MA, Elshal AM, Elhilali MM: Reoperation after holmium laser enucleation of the prostate for management of benign prostatic hyperplasia: assessment of risk factors with time to event analysis. J Endourol 2015; 29: 797–804.
11.
Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ: Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 2009; 27: 541–545.
12.
Bach T, Netsch C, Pohlmann L, Herrmann TR, Gross AJ: Thulium:YAG vapoenucleation in large volume prostates. J Urol 2011; 186: 2323–2327.
13.
Gilling P: Holmium laser enucleation of the prostate (HoLEP). BJU Int 2008; 101: 131–142.
14.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.
15.
Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F: The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol 2011; 29: 205–210.
16.
Vincent MW, Gilling PJ: HoLEP has come of age. World J Urol 2015; 33: 487–493.
17.
Marien T, Kadihasanoglu M, Miller NL: Holmium laser enucleation of the prostate: patient selection and perspectives. Res Rep Urol 2016; 8: 181–192.
18.
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al: Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58: 384–397.
19.
Netsch C, Becker B, Tiburtius C, Moritz C, Becci AV, Herrmann TR, et al: A prospective, randomized trial comparing thulium vapoenucleation with holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic obstruction: perioperative safety and efficacy. World J Urol 2017; 35: 1913–1921.
20.
Rieken M, Bachmann A: Laser treatment of benign prostate enlargement – which laser for which prostate? Nat Rev Urol 2014; 11: 142–152.
21.
Bach T, Netsch C, Haecker A, Michel M-S, Herrmann TR, Gross AJ: Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol 2010; 28: 39–43.
22.
Gilling PJ: Laser enucleation is increasingly becoming the standard of care for treatment of benign prostatic hyperplasia of all sizes. Eur Urol 2013; 63: 868–869.
23.
Kuntz RM, Lehrich K, Ahyai SA: Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008; 53: 160–166.
24.
Becker B, Buttice S, Magno C, Gross AJ, Netsch C: Thulium vaporesection of the prostate and thulium vapoenucleation of the prostate: a retrospective bicentric matched-paired comparison with 24-month follow-up. Urol Int 2018; 100: 105–111.
25.
Zhang F, Shao Q, Herrmann TR, Tian Y, Zhang Y: Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology 2012; 79: 869–874.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.